Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Gallagher C, Pohlmann PR, Nunes R, Herbolsheimer P, Warren R, Srichai MB, Hofmeyer M, Cunningham A, Timothee P, Asch FM, Shajahan-Haq A, Tan MT, Isaacs C, Swain SM. Lynce F, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2019 Jun;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9. Breast Cancer Res Treat. 2019. PMID: 30852761 Free PMC article. Clinical Trial.
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
Stearns V, Gallagher A, Kleer CG, Singh B, Freedman M, Haddad BR, Isaacs C, Warren R, Brown M, Cullen J, Trock B, Hayes DF. Stearns V, et al. Among authors: isaacs c. Clin Cancer Res. 2004 Dec 15;10(24):8332-40. doi: 10.1158/1078-0432.CCR-04-0297. Clin Cancer Res. 2004. PMID: 15623610 Clinical Trial.
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Marcom PK, Isaacs C, Harris L, Wong ZW, Kommarreddy A, Novielli N, Mann G, Tao Y, Ellis MJ. Marcom PK, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2007 Mar;102(1):43-9. doi: 10.1007/s10549-006-9307-8. Epub 2006 Aug 8. Breast Cancer Res Treat. 2007. PMID: 16897431 Clinical Trial.
Practical aspects of delivering hereditary cancer risk counseling.
DeMarco TA, Smith KL, Nusbaum RH, Peshkin BN, Schwartz MD, Isaacs C. DeMarco TA, et al. Among authors: isaacs c. Semin Oncol. 2007 Oct;34(5):369-78. doi: 10.1053/j.seminoncol.2007.07.003. Semin Oncol. 2007. PMID: 17920890 Review.
501 results